Istanbul Dentistry School Joins Clinerion’s PRS Platform
Basel, Switzerland – The Dentistry School of the University of Istanbul (IU), Istanbul, Turkey, joins Clinerion’s Patient Recruitment System platform, opening up new patient populations for patient recruitment and new clinical expertise areas for the running of clinical trials.
By joining Patient Recruitment System (PRS), patients at the Dentistry School can be matched to clinical research studies seeking to recruit patients for trials. Pharmaceutical companies using Clinerion’s PRS will be able to evaluate the patient population of the dental hospital during the development of the trial protocol and the site selection steps of their drug trials, potentially bringing more international clinical research to Istanbul University. The hospital itself can rigorously identify and quickly enroll its own patients for trials using PRS.
The IU Dentistry School specializes in all fields of dentistry, from Oral and Maxillofacial Surgery to Prosthodontics, from Periodontology to Pediatric Dentistry, Endodontics to Orthodontics. The hospital treated over 97,500 patients in the past year.
Clinerion’s Patient Recruitment System finds patients for clinical trials by checking clinical trial requirements against patient data from the databases of connected hospitals in real-time. Clinerion’s hospital coverage in Turkey alone currently comprises hospitals in Istanbul, Konya and Malatya with a catchment area of 30 M people. PRS currently has access to over 350 M data entries. Additional use cases for PRS include Market Access Studies and Real World Data Analysis.
“We see a great benefit for our patients as well as for our hospital,” says Prof. Dr. Gülsüm Ak, the Dean of the Dentistry School. “PRS will bring our patients access to innovative new treatments, while the Dentistry School will gain higher exposure and visibility for leading edge clinical research.”
“The Dental Hospital of the University of Istanbul brings PRS new clinical expertise areas for the running of clinical trials and new patient populations for patient recruitment, expanding Clinerion’s hospitals coverage,” says BariÅ ErdoÄan, Clinerion’s Country Head Turkey. “The continued expansion of PRS in Turkey shows the productive and material benefits brought by Clinerion to clinical trials in Turkey.”
“We are thrilled to welcome the Dental Hospital of Istanbul University to the Clinerion PRS platform,” says Ulf Claesson, CEO of Clinerion. “PRS will boost the number, quality and efficiency of their clinical trials activities, while also bringing their patients access to advanced medication.”
For more on Clinerion’s Patient Recruitment System: www.clinerion.com/index/OverviewOurSolutions/PatientRecruitmentSystem
About Clinerion
Clinerion is an international technology services company offering highly scalable electronic patient recruitment solutions to increase efficiency and quality in clinical research. The company's Patient Recruitment System connects to and leverages existing electronic medical records. Following international privacy and confidentiality standards, Clinerion's solutions pseudonymize, enrich and normalize those records and facilitate real-time patient recruitment for clinical trials. Clinerion website: www.clinerion.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
